#2 - Moderna (NASDAQ:MRNA)
The bullish narrative for Moderna (NASDAQ:MRNA) is nearly identical to that of Pfizer. Whether or not, a curated vaccine will be required to effectively deal with the omicron variant, Moderna is in a position for another strong year.
Where the case for Moderna becomes different and potentially more bullish is when you look beyond the pandemic. The company’s vaccine has been a significant proof of concept for mRNA technology. This means that Moderna may find it easier to get the approval of the technology over a wide spectrum of vaccines. Should that happen, the ceiling for MRNA stock may be much higher than that of Pfizer.
MRNA stock is up 147% for the year (as of this writing) and that’s with the stock being down sharply from its all-time high set earlier this year. That drop occurred after the company missed sharply on both its top and bottom lines when it reported earnings in November.
However, as Ushman points out Moderna’s stock is displaying a very similar movement to Pfizer. And if the company can maintain support above its closest Anchored Volume Weighted Average Price, it is giving investors a strong technical setup.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More - Current Price
- $39.39
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 12 Hold Ratings, 4 Sell Ratings.
- Consensus Price Target
- $79.50 (101.8% Upside)
